Cofactor Genomics to provide solid tumor immune profiling for Genocea Biosciences
San Francisco, December 4, 2018 -- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, today announced a pilot study to evaluate use of Cofactor’s ImmunoPrismTM assay in Genocea Biosciences’ Phase 1/2a clinical trial testing the safety and efficacy ...
Cofactor Genomics Launches ImmunoPrism Immune Profiling Kit, for Use in Clinical Sequencing Laboratories
San Francisco, October 30, 2018 -- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today the launch of a RNA-based immune profiling kit developed for laboratories wishing to derive the immune composition of tumor samples. The tumor’s i...
Cofactor Genomics Announces Clinical Validation of its Tumor Immune-Profiling Assay, ImmunoPrism
SAN FRANCISCO, CA -- Oct. 4, 2018 -- Cofactor Genomics, a clinical RNA sequencing and translational assay developer, announced today that its laboratory has successfully completed a rigorous validation of ImmunoPrismTM, its comprehensive, quantitative, solid tumor immune-profi...